Functional blind spot of unpublished causal GWAS variants and bottleneck in disease pathogenesis Metabolic liver disease is a multifactorial chronic condition whose incidence has exploded in parallel with modern dietary changes and the metabolic syndrome. While standard genome-wide association study (GWAS) guidelines have successfully identified numerous disease‑risk loci statistically, more than 90 % of these variants reside in non‑coding regions that do not directly code for proteins, creating a critical blind spot that prevents determination of which downstream genes’ expression they drive. The inability to computationally control the noise between simple statistical association and true biological causality has long constituted a technical bottleneck that hampers the establishment of precision‑targeted drug pipelines aimed at preventing excessive hepatic lipid accumulation.

Integration of MPRA and CRISPR screening: chromatin‑accessibility tensor mapping of thousands of variants In the study published in Nature Genetics on 2 June, we eliminated this functional‑discovery barrier by fully integrating massively parallel reporter assay (MPRA) high‑throughput technology with a CRISPR‑based genomic engineering matrix. The team mapped thousands of disease‑associated non‑coding genomic sets in silico and directly measured fine‑scale fluctuations in transcriptional regulatory activity and chromatin accessibility at high throughput. The results demonstrated for the first time that specific causal variants precisely disrupt allosteric docking sites of key transcription factors, thereby non‑linearly amplifying or attenuating expression of downstream metabolic target genes, establishing molecular causality.

Pinpointing causal variants in hepatic metabolic pathways and achieving precision preventive stratification Epidemiological tracing of omics kinetics revealed that the true causal variants obscured by statistical noise, together with the downstream hepatic lipid‑metabolism pathways they govern, can be precisely stratified. This enables isolation of false‑positive confounding variables within a patient’s polygenic risk score (PRS) to below baseline levels, delivering unparalleled precision. Clinicians can now move beyond a generic statistical warning of “high fatty‑liver risk” to quantitatively assess how a patient’s variant diminishes binding affinity of specific metabolic enzymes, and to design individualized preventive guidelines based on this high‑resolution backbone.

Establishing a programmable early‑diagnosis standard and launching next‑generation liver‑disease companion‑diagnostic panels The integrated genetics‑and‑molecular‑pharmacology data dossier redefines the diagnostic standard for metabolic liver disease, shifting from post‑hoc ultrasound and simple biochemical liver‑function scans to a programmable liquid‑biopsy infrastructure that computationally filters causal‑variant docking matrices to infer disease risk. This framework provides the computational correction factors that maximize drug‑target discovery success in premium metabolic‑disease R&D pipelines of multinational pharmaceutical companies. The established MPRA‑CRISPR variant‑sensitivity matrix will serve as a master asset that can dramatically accelerate global IND approval timelines for next‑generation early‑diagnosis kits and companion‑diagnostic (CDx) platforms.